PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children
Status:
Active, not recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
This is an open label study of everolimus in children with recurrent or progressive low-grade
glioma.
Phase:
Phase 2
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
Novartis Pharmaceuticals Pacific Pediatric Neuro-Oncology Consortium The Pediatric Low Grade Astrocytoma (PLGA) Foundation The Pediatric Low Grade Astrocytoma Foundation